Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.16
Views: 1907

Dr Sibylle Loibl - German Breast Cancer Group

Dr Loibl discusses current indications for CDK 4/6 inhibitors (plus antiestrogen) as well as possible biomarkers at the 'Coming of Age for CDK 4/6 Inhibitors' symposium at ESMO 2016.

Her presentation is followed by a question and answers session.

Supported by a grant from Pfizer Inc.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation